In situ formation of peptidic nanofibers can fundamentally optimize the quality of immune responses against HIV vaccine.

Herein, we report that the in situ formed peptidic nanofibers facilitate the induction of multiple crucial immunities against HIV DNA vaccine, including polyfunctional T cell response, broad IgG subclasses response, and V1/V2 loop-specific antibody response, all of which can hardly be triggered by HIV DNA vaccine alone. Such novel in situ formation fundamentally overcomes the big hurdle for the applications of such nanofibers, which previously can only trigger these crucial immune responses via adding exogenous alkaline phosphatase. Such robustness of peptidic nanofibers for inducing crucial immune responses may allow better inhibition against HIV than reported materials.

[1]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[2]  Xuetao Cao,et al.  The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. , 2014, Journal of autoimmunity.

[3]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[4]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[5]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[6]  Georgia D Tomaras,et al.  HIV-1-specific antibody responses during acute and chronic HIV-1 infection , 2009, Current opinion in HIV and AIDS.

[7]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[8]  D. Davis,et al.  Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. , 2013, Blood.

[9]  Peng Huang,et al.  Tumor-Specific Formation of Enzyme-Instructed Supramolecular Self-Assemblies as Cancer Theranostics. , 2015, ACS nano.

[10]  G. Liang,et al.  Enzymatic Self-Assembly of Nanostructures for Theranostics , 2012, Theranostics.

[11]  Bing Xu,et al.  Imaging enzyme-triggered self-assembly of small molecules inside live cells , 2012, Nature Communications.

[12]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[13]  J. Mascola,et al.  The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.

[14]  R. Kurth,et al.  Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. , 1986, The Journal of infectious diseases.

[15]  Wei Zhang,et al.  A peptide-based nanofibrous hydrogel as a promising DNA nanovector for optimizing the efficacy of HIV vaccine. , 2014, Nano letters.

[16]  F. Pereyra,et al.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. , 2010, AIDS research and human retroviruses.

[17]  Bing Xu,et al.  Pericellular hydrogel/nanonets inhibit cancer cells. , 2014, Angewandte Chemie.

[18]  K. Okkenhaug,et al.  IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase–Dependent Upregulation of CD86 on B Cells , 2014, The Journal of Immunology.

[19]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[20]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[21]  Persephone Borrow,et al.  The immune response during acute HIV-1 infection: clues for vaccine development , 2009, Nature Reviews Immunology.

[22]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[23]  Mario Roederer,et al.  Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses , 2007, The Journal of experimental medicine.

[24]  O. Frey,et al.  Lack of IL-4 receptor expression on T helper cells reduces T helper 2 cell polyfunctionality and confers resistance in allergic bronchopulmonary mycosis , 2012, Mucosal Immunology.

[25]  S. Deeks,et al.  Immunologic strategies for HIV-1 remission and eradication , 2014, Science.

[26]  T. Rothstein,et al.  IL-4 Upregulates Igα and Igβ Protein, Resulting in Augmented IgM Maturation and B Cell Receptor–Triggered B Cell Activation , 2013, The Journal of Immunology.

[27]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[28]  J. Meng,et al.  Super-paramagnetic responsive nanofibrous scaffolds under static magnetic field enhance osteogenesis for bone repair in vivo , 2013, Scientific Reports.

[29]  P. Nadeau,et al.  Modulation of CD40-activated B lymphocytes by N-acetylcysteine involves decreased phosphorylation of STAT3. , 2012, Molecular immunology.

[30]  David A. Price,et al.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.